American care at home, American strength at the front—Pirouette is building nationally important manufacturing capabilities in Portsmouth, New Hampshire to ensure critical medicines can be delivered quickly, accurately, and with confidence in any environment. While medicines in the portfolio are advancing through FDA pathways and are not yet approved, the next‑generation OnePush auto‑injector is fully developed to make injections as easy as pushing a button wherever duty calls.
Learn More
OnePush uses a fully automatic, hidden needle with smooth, controlled insertion to minimize needle sensation and eliminate needle visibility before, during, and after use, reducing hesitation and strengthening adherence in civilian and military settings. Fixed, prefilled dosing and human‑factors simplicity help reduce delay and errors—supporting decisive care for life‑saving rescue and reliable self‑care for chronic therapies.
Engineered for battlefield‑grade durability and FDA‑aligned reliability targets for life‑or‑death use, with performance designed for first‑try success under pressure.
One‑touch intramuscular or subcutaneous delivery is engineered to help reduce cognitive load for soldiers and first responders operating in contested environments and CBRN scenarios. The compact profile integrates into IFAKs and public safety kits, supporting rapid deployment across rescue and chronic‑care pairings as development advances.
All product candidates are investigational; safety and effectiveness have not been established, and any future labeling and indications will be determined by regulatory review.
From town centers to highways, firefighters, law enforcement, and EMS require decisive tools that deliver a dose in seconds with minimal steps under stress. OnePush pairs a hidden, fully automatic needle with smooth, controlled insertion to reduce hesitation and injects through thick clothing—supporting confident use in chaotic scenes. Intramuscular delivery allows administration away from the nose and mouth, which public health guidance notes can reduce rescuer exposure risk in certain scenarios.
Pirouette is advancing an investigational naloxone auto‑injector configured for layperson and first‑responder use, with fixed, prefilled dosing designed to support rapid community overdose reversal workflows. National guidance affirms naloxone can be administered intranasally or by intramuscular injection, and that repeat dosing may be needed within minutes when breathing does not recover. DoD‑supported naloxone countermeasures and high dose IM labeling for military and chemical incident responders underscore the operational relevance of auto‑injectors for high‑potency opioid threats.
Because emergency arrivals can be delayed by distance, traffic, or concurrent incidents, stocking simple, prefilled auto‑injectors helps communities intervene sooner when opioids are suspected. First‑responder and layperson studies demonstrate that auto‑injectors are designed for ease of use in emergencies, complementing training and enabling rapid deployment in the field.
All Pirouette product candidates are investigational; safety and effectiveness have not been established, and any future labeling and indications will be determined by regulatory review.